🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,444 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11707536

Viral vectors encoding recombinant FVIII variants with increased expression for gene thera

Takeda Pharmaceutical Company Limited · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11701355

Levosimendan for treating pulmonary hypertension with heart failure with preserved ejectio

TENAX THERAPEUTICS, INC. · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11697669

Hemi-citrate salts of GABA-A positive allosteric modulator and crystalline form thereof

PRAXIS PRECISION MEDICINES, INC. · Granted Tue Jul 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11680254

Engineered meganucleases specific for recognition sequences in the PCSK9 gene

Precision BioSciences, Inc. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679143

FGF21 variant, fusion protein and application thereof

SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679159

Compositions for transfecting resistant cell types

Precision Nanosystems ULC · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11680090

Interleukin-2 fusion proteins and uses thereof

Medicenna Therapeutics Inc. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11667890

Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

Iovance Biotherapeutics, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11666547

Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorde

Northwestern University · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11666602

Treatment of pulmonary arterial hypertension with mesenchymal stem cells

United Therapeutics Corporation · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11661601

Methods for modulating FMR1 expression

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11649207

Formulations of T-type calcium channel modulators and methods of use thereof

PRAXIS PRECISION MEDICINES, INC. · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642390

Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11639504

Methods and compositions for regulation of transgene expression

Sangamo Therapeutics, Inc. · Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11638708

Method of treatment of aggression

Supernus Pharmaceuticals, Inc. · Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11633483

Modulators of PCSK9 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11634711

Methods and compositions for modulating apolipoprotein (a) expression

Ionis Pharmaceuticals, Inc. · Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11629146

Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity

PRAXIS PRECISION MEDICINES, INC. · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11629349

RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical comp

Arrowhead Pharmaceuticals, Inc. · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11613752

Compositions and methods for modulating PKK expression

Ionis Pharmaceuticals, Inc. · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11607412

Levosimendan for treating pulmonary hypertension with heart failure with preserved ejectio

TENAX THERAPEUTICS, INC. · Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11602559

HIV-1 Env fusion peptide immunogens and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596671

Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with in

Takeda Pharmaceutical Company Limited · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11590179

Bifidobacterium longum able to beneficially modulate immune response to respiratory virus

PrecisionBiotics Group Limited · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted